
Lung Cancer
Latest News
Video Series

Latest Videos
Shorts

Podcasts
More News

The oral, once-daily EGFR inhibitor is now in specialty distribution for patients whose disease progressed after platinum-based chemotherapy.

Following WCLC 2026, Katherine Kuhns details how perioperative immunotherapy, AI patient tools, and wearables are transforming thoracic surgical nursing care.

At WCLC 2026, Kaitlyn Gregory details key oncology nursing insights into exercise, caregiver stress, screening models, and APP-led supportive care.

FDA approves sNDA for taletrectinib (Ibtrozi) in ROS1+ NSCLC with updated DOR of nearly 50 months.

The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.

FDA grants accelerated approval to sevabertinib (Hyrnuo) for HER2 TKD-mutant non-squamous NSCLC, expanding access to treatment-naive patients.

Beth Sandy, CRNP, of Penn Medicine discusses therapeutic advances in thoracic oncology, toxicity management, and overcoming financial barriers.

A new study shows physical activity increases tumor-killing T cells and reduces suppressive Tregs in obese lung environments, boosting outcomes.

Oncology nurses discuss managing lung cancer as a chronic disease, addressing long-term symptoms, financial toxicity, and psychosocial care.

The FDA approved zidesamtinib for metastatic ROS1-positive NSCLC following prior kinase inhibitor therapy, offering hope for patients with resistance.

Pamela Plasket, RN, discusses the evolving role of oncology nurses as lung cancer patients survive longer on advanced therapies like BiTEs.

A study conducted by SEER and Medicare revealed that nearly half of older patients diagnosed with metastatic non-small cell lung cancer never received systemic therapy.

Gotistobart reduced death risk by 54% and doubled 12-month survival vs chemo in pretreated advanced squamous NSCLC, per PRESERVE-003 results.

Nuvalent submitted an NDA for neladalkib in TKI-pretreated ALK+ NSCLC, supported by ALKOVE-1 data showing systemic and intracranial activity with tolerability.

Zongertinib elicited responses in patients with advanced HER2-mutant NSCLC, showing intracranial efficacy in those with active brain metastases, per phase 1b Beamion LUNG-1 data.

Adagrasib shows efficacy in elderly patients with KRAS G12C-mutant NSCLC and an ECOG PS of 0-1, while those with a PS of 2 see limited survival benefit but QOL improvements.

Calderasib, a potent KRAS G12C inhibitor, demonstrated improved outcomes in patients with metastatic NSCLC, especially when combined with pembrolizumab.






















































































